Aurora Cannabis (Aurora Cannabis Stock Quote, Chart, News, Analysts, Financials TSX:ACB) reported stronger fourth-quarter Adjusted EBITDA than any quarter in fiscal 2024, though momentum investors reacted to slowing sequential growth, according to Roth Capital analyst Bill Kirk.
In a June 19 note, Kirk reiterated a “Neutral” rating and lowered his 12-month price target to $7 from $8, citing concerns about decelerating profitability despite Aurora’s margin expansion, debt-free status, and leadership in international medical cannabis markets. Kirk said the quarter was better than the stock reaction.
Aurora Cannabis produces, distributes, and sells cannabis products, as well as indoor cultivation systems and hemp-based food items. It operates through Canadian and international cannabis segments and is…
